Home > Resources > Company Profiles > Amgen, Incorporated

Amgen, Incorporated (AMGN)

Email Confirmation

Kevin W. Sharer , CEO/Chairman of the Board/President/Director

www.amgen.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A biotechnology company, which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

Portfolio Articles

Relocation, Relocation, Relocation
When public companies hire C.E.O.'s, shareholders often supply the moving vans—and occasionally the homes too.

May 12 2008
Good News for Pharma Stocks
The sector soars after three companies blow away expectations, and Amgen reports positive research news on its biggest seller.

Apr 19 2007

See more news on this company

News Feeds

Final Glance: Biotechnology companies AP
Sep 05 2008
Midday Glance: Biotechnology companies AP
Sep 05 2008
Early Glance: Biotechnology companies AP
Sep 05 2008
Amgen executive joins Aryx Therapeutics board AP
Aug 29 2008
Amgen to discontinue discounts on anemia drug: report Reuters
Aug 28 2008
Ahead of the Bell: Amgen AP
Aug 25 2008
FDA clears Amgen drug for blood-clotting disorder AP
Aug 22 2008
Amgen shares rise on positive Goldman Sachs review AP
Aug 14 2008

Press Releases

Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers Sep-04-2008, 03:22PM EDT
BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD Aug-29-2008, 10:50AM EDT
NSTA New Science Teacher Academy Expands With the Support of Three New Organizations Aug-27-2008, 12:00PM EDT
Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report Aug-27-2008, 10:32AM EDT
FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP Aug-22-2008, 01:50PM EDT

News From Around the Web

News

Kidney Research UK Launches First Ever National Kidney Disease Screening Pilot (Medical News Today)

Sep 07 2008
FDA orders stronger warnings for 4 arthritis drugs (Stamford Advocate)

Sep 07 2008
Cytokinetics starts third mid-stage test of heart drug (BizJournals)

Sep 06 2008
Amgen's Fremont operation gets new site head (BizJournals)

Sep 06 2008
Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers (Medical News Today)

Sep 06 2008
CFA: Applications Given Early Antitrust Clearance By FTC (Wall Street Journal)

Sep 05 2008
Early Glance: Biotechnology companies (Boston Globe)

Sep 05 2008
Your Funds on Drugs (U.S. News & World Report)

Sep 05 2008
Midday Glance: Biotechnology companies (Boston Globe)

Sep 04 2008

Blogs

Direct To Consumer Ads: Wasted Money? (In the Pipeline)

Sep 03 2008

Employees

Number of Employees: 17,400

Revenue per Employee: $738,550

Top Executives

Thomas J. Flanagan, Chief Information Officer/Senior VP

David J. Scott, Senior VP/Secretary/General Counsel

Dr. Fabrizio Bonanni, Executive VP, Divisional

Michael A. Kelly, Chief Accounting Officer/Vice President, Divisional

Brian McNamee, Divisional Senior VP

Dr.Roger M. Perlmutter, M.D., Ph.D., Divisional Executive VP

Robert A. Bradway, CFO/Executive VP

Madhu Balachandran, Senior VP, Divisional

George J. Morrow, Divisional Executive VP

Board of Directors

David J. Scott, Senior VP/Secretary/General Counsel

Dr. Vance D. Coffman, Director

Leonard D. Schaeffer, Director

Edward V. Fritzky, Director

Frank J. Biondi, Jr., Director

Jerry D. Choate, Director

Frederick W. Gluck, Director

Frank C. Herringer, Director

Judith C. Pelham, Director

Dr. David Baltimore, Director

Admiral J. Paul Reason, Director

Dr.Gilbert S. Omenn, Director

Financials

Quarterly

Annual

Income Statement	07/2008	04/2008	01/2008	11/2007
Sales	588 Mil.	620 Mil.	680 Mil.	494 Mil.
Gross Operating Profit	3.18 Bil.	2.99 Bil.	3.06 Bil.	3.12 Bil.
Operating Income before D & A (EBITDA)	1.46 Bil.	1.42 Bil.	1.24 Bil.	1.61 Bil.
Total Income Before Interest Expenses (EBIT)	1.19 Bil.	1.46 Bil.	1.43 Bil.	393 Mil.
Total Net Income	941 Mil.	1.14 Bil.	835 Mil.	201 Mil.
Basic EPS, Total	0.87	1.04	0.77	0.19
Diluted EPS, Total	0.87	1.04	0.76	0.18

BALANCE STATEMENT	07/2008	04/2008	01/2008	11/2007
Cash and Equivalents	8.48 Bil.	8.65 Bil.	7.15 Bil.	1.39 Bil.
Total Assets	14.53 Bil.	14.53 Bil.	13.04 Bil.	11.71 Bil.
Total Liabilities	5.43 Bil.	5.95 Bil.	6.18 Bil.	4.23 Bil.
Total Capitalization	28.71 Bil.	28.26 Bil.	27.05 Bil.	28.08 Bil.

Cash Flow	07/2008	04/2008	01/2008	11/2007
Net Cash From Continuing Operations	NA	NA	NA	3.87 Bil.
Net Cash From Investing Activities	NA	NA	NA	-1.3 Bil.
Net Cash From Financing Activities	NA	NA	NA	-2.47 Bil.
Net Change in Cash & Cash Equivalents	NA	NA	NA	106 Mil.

Income Statement	2008	2007	2006	2005
Sales	2.85 Bil.	1.5 Bil.	1.59 Bil.	1.33 Bil.
Gross Operating Profit	11.92 Bil.	12.77 Bil.	10.84 Bil.	9.22 Bil.
Operating Income before D & A (EBITDA)	5.3 Bil.	6.03 Bil.	5.74 Bil.	4.64 Bil.
Total Income Before Interest Expenses (EBIT)	3.98 Bil.	4.15 Bil.	4.97 Bil.	3.43 Bil.
Total Net Income	3.17 Bil.	2.95 Bil.	3.67 Bil.	2.36 Bil.
Basic EPS, Total	2.83	2.51	2.97	1.86
Diluted EPS, Total	2.82	2.48	2.93	1.81

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	7.15 Bil.	1.28 Bil.	1.84 Bil.	1.53 Bil.
Total Assets	13.04 Bil.	11.71 Bil.	9.24 Bil.	9.17 Bil.
Total Liabilities	6.18 Bil.	7.02 Bil.	3.6 Bil.	4.16 Bil.
Total Capitalization	27.05 Bil.	26.1 Bil.	24.41 Bil.	23.64 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	5.39 Bil.	4.91 Bil.	3.7 Bil.
Net Cash From Investing Activities	NA	-5.13 Bil.	-59 Mil.	-1.4 Bil.
Net Cash From Financing Activities	NA	-815 Mil.	-4.54 Bil.	-1.61 Bil.
Net Change in Cash & Cash Equivalents	NA	-557 Mil.	314 Mil.	689 Mil.

Amgen, Incorporated (AMGN)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request